June 20, 2011 /PRNewswire/ -- Abbott announced today that the U.S. Food and Drug Administration (FDA) has approved a new 45 mg for six-month administration formulation of Lupron Depot ...

of a new six-month 45-mg formulation of Lupron® Depot (leuprolide acetate for depot suspension) for use in the palliative treatment of advanced prostate cancer. Palliative treatment helps to ...

This open-label study evaluated the efficacy and safety of a new leuprolide acetate 45 mg 6-month depot formulation in 151 men with prostate cancer who received 2 intramuscular injections ...

The FDA is reviewing Abbott’s supplemental New Drug Application for a new six-month 45-mg formulation of Lupron Depot (leuprolide acetate for depot suspension) for the palliative treatment of ...

Abbott announced Monday the approval of a 45-mg, six-month formulation of Lupron Depot (leuprolide acetate) for advanced prostate cancer. Previous formulations have allowed patients to receive the ...

Leuprolide acetate 45mg; depot susp for IM inj; preservative-free. Give as single IM inj into gluteal area, anterior thigh or deltoid; rotate inj sites. 45mg once every 6 months (24 weeks).

Cipla has launched Leuprolide Acetate Injection Depot ... 505b2 regulatory pathway Leuprolide Acetate Injection Depot contains 225 mg of leuprolide acetate for 3-month administration given as ...

Leuprolide acetate injection depot contains 22.5 mg of leuprolide acetate for 3-month administration given as a single dose injection. It is supplied as lyophilized microspheres in a single dose vial ...

The product was approved by the United States Food and Drug Administration (USFDA) Leuprolide Acetate Injection Depot contains 22.5 mg of leuprolide acetate for 3- month administration given as a ...